<span item_type="fundamental" item_id="f79617c07e38521eb5026f558564eef9" counter_id="ST/US/CLNNW" env="prod"></span><span item_type="announcement" item_id="582309946286543873" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 15 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.85.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -5.039 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $15,000 for the three months ended September 30, 2025, compared to $87,000 for the same period in 2024, representing an 83% decrease. For the nine months ended September 30, 2025, total revenue was $123,000, compared to $251,000 for the same period in 2024, a 51% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Loss from Operations</strong>: - $5,648,000 for the three months ended September 30, 2025, compared to - $7,815,000 for the same period in 2024, a 28% decrease. For the nine months ended September 30, 2025, the loss from operations was - $15,588,000, compared to - $24,438,000 for the same period in 2024, a 36% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li><li><strong>Net Loss</strong>: - $8,777,000 for the three months ended September 30, 2025, compared to - $7,986,000 for the same period in 2024, a 10% increase. For the nine months ended September 30, 2025, the net loss was - $16,947,000, compared to - $25,851,000 for the same period in 2024, a 34% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $13,747,000 for the nine months ended September 30, 2025, compared to - $16,461,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $9,448,000 for the nine months ended September 30, 2025, compared to - $4,057,000 used in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development Expense</strong>: $3,513,000 for the three months ended September 30, 2025, compared to $4,471,000 for the same period in 2024, a 21% decrease. For the nine months ended September 30, 2025, research and development expenses were $8,508,000, compared to $14,490,000 for the same period in 2024, a 41% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li><li><strong>General and Administrative Expense</strong>: $2,150,000 for the three months ended September 30, 2025, compared to $3,413,000 for the same period in 2024, a 37% decrease. For the nine months ended September 30, 2025, general and administrative expenses were $7,183,000, compared to $10,147,000 for the same period in 2024, a 29% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to submit a New Drug Application (NDA) for CNM-Au8 under an accelerated approval pathway in the first quarter of 2026, contingent on positive data from ongoing studies. They also plan to commence a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026, contingent on funding.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring additional funding options, including equity financing, debt financing, and collaboration arrangements, to support its operations and strategic initiatives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925034613/clnn20250930_10q.htm"></span></li></ul>

CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 15 K